Dossier assessment
Daratumumab (newly diagnosed multiple myeloma, unsuitable for stem cell transplantation) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Report documents
-
Extract of dossier assessment
Daratumumab (newly diagnosed multiple myeloma, unsuitable for stem cell transplantation) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
-
Dossier assessment
Daratumumab (newly diagnosed multiple myeloma, unsuitable for stem cell transplantation) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Dossier assessment
Adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant
Hint of considerable added benefit
Press releases
Daratumumab in multiple myeloma: reassessment shows hint of considerable added benefit
Additional information
Federal Joint Committee (G-BA)
2022-03-18 A G-BA decision was published.
Project details
- Project no.
- A21-126
- Commission
- Commission awarded on 01.10.2021 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2022-01-03.
Connected Projects
-
Dossier assessment
Daratumumab (multiple myeloma, stem cell transplant) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V
Status: Commission completed
-
Addendum
Daratumumab (multiple myeloma) - Addendum to Commission A21-126
Status: Commission completed
-
Dossier assessment
Daratumumab (smouldering multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (newly diagnosed multiple myeloma, ineligible for stem cell transplant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (newly diagnosed multiple myeloma, suitable for autologous stem cell transplant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (systemic light chain amyloidosis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed